Cellular Target Engagement Assay Development

Cellular Target Engagement Assay Development: A RIPK1 Case Study

Demonstrating cellular target engagement is essential for confirming that compounds bind and engage their target in a physiologically relevant environment. In this poster, Sygnature Discovery presents the development and validation of a cellular target engagement assay for receptor-interacting serine/threonine-protein kinase 1 (RIPK1), a key regulator of inflammatory and programmed cell death pathways

Using enzyme fragment complementation (EFC)-based technology, the assay quantifies compound-induced thermal stabilization of RIPK1 in living cells, enabling the generation of cellular target engagement EC₅₀ values with minimal hands-on time. The study demonstrates successful assay optimization and validation using established RIPK1 inhibitors, with cellular target engagement data aligning with functional activity in a necroptosis model.

Study Highlights

• Development of a robust cellular target engagement assay for RIPK1
• Optimization of assay conditions for sensitive detection in live cells
• Quantitative measurement of cellular target engagement and EC₅₀ values in live cells
• Validation using established RIPK1 inhibitors with expected rank-order potency
• Correlation of target engagement data with activity in a functional necroptosis model

Supporting Cellular Target Engagement Studies

Cellular target engagement studies provide critical evidence that compounds reach and interact with their intended target in a biologically relevant setting. This RIPK1 case study highlights Sygnature Discovery’s expertise in developing and validating fit-for-purpose cellular assays that support hit validation, potency ranking, lead optimization, and mechanism-of-action studies.

By combining assay development, cellular pharmacology, and translational biology expertise, our scientists generate actionable data that helps clients make informed decisions and progress promising drug candidates with greater confidence.